诺思格收盘上涨1.71%，滚动市盈率30.07倍，总市值43.08亿元

Company Overview - Norsg has a closing price of 44.6 yuan, with an increase of 1.71%, resulting in a rolling PE ratio of 30.07 times and a total market value of 4.308 billion yuan [1] - The company operates in the medical services industry, which has an average PE ratio of 38.49 times and a median of 39.26 times, placing Norsg at the 23rd position in the industry ranking [1] Shareholding and Institutional Investment - As of the first quarter of 2025, there are 12 institutions holding shares in Norsg, including 7 funds and 5 other entities, with a total shareholding of 32.7994 million shares valued at 1.685 billion yuan [1] Business Operations - Norsg (Beijing) Pharmaceutical Technology Co., Ltd. provides comprehensive integrated services for drug clinical research and development for global pharmaceutical companies and research institutions [1] - The main services offered include clinical trial operation services, clinical trial site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] Financial Performance - In the first quarter of 2025, Norsg reported an operating income of 173 million yuan, a year-on-year decrease of 2.53%, and a net profit of 26.0737 million yuan, reflecting a year-on-year increase of 13.12%, with a sales gross margin of 36.53% [1]